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Abstract
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of
the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins
neutrophil gelatinase associated lipocalin (NGAL) and TGF-b family member macrophage inhibitory cytokine-1 (MIC-1) are
proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as
diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic
efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients
(n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP,
n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker
commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to
HCs. The mean (6 standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2),
219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were
found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%,
respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78%
respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic
cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9
significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with
CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs.
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Introduction
Despite decades of research, the prognosis for pancreatic cancer
(PC) remains dismal, with an overall five-year survival rate of only
about 5% [1]. A significant contributor to the poor prognosis of
PC is the fact that the cancer often remains undiscovered until an
advanced stage. Available techniques for the diagnosis of PC
present several difficulties chiefly their invasive nature, need for
specialized training, observer bias and the high cost to the
healthcare system. Further, it has been demonstrated through
experiments in animal models that molecular changes precede the
appearance of changes in pancreatic architecture (detected by
imaging techniques) [2]. Hence, there has been a growing
emphasis on the identification of molecular markers that can
identify PC at an early and potentially resectable stage. Body
fluids, such as blood, urine, bile and pancreatic juice represent
a promising source of potential biomarkers. Currently, the only
biomarker that is approved for use in PC is CA19-9 which is
recommended to follow the progression of PC, but not for
diagnostic use. We have previously reported that neutrophil
gelatinase associated lipocalin (NGAL), a 24 kDa glycoprotein, is
differentially upregulated during the progression of PC. Further, in
a small set of samples we showed that plasma NGAL levels were
significantly elevated in PC patients compared to healthy controls
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[3]. Recently, El-Mesallamy et al. observed significant increase in
NGAL levels in PC patients with pre-existing diabetes (142 ng/ml)
in comparison to diabetic patients (66.7 ng/ml) and non-diabetic
healthy controls (37.8 ng/ml). With sensitivity and specificity of
75% and 87% in differentiating PC from non-PC cases NGAL
came up as potential adipokine [4]. Macrophage inhibitory
cytokine (MIC-1), a distant member of the transforming growth
factor b (TGF-b) family of cytokines, was originally identified as
a gene expressed in the context of macrophage activation [5]. In
a previous study, it was shown to be differentially expressed in PC
tissues and elevated in the serum of PC patients compared to both
healthy controls and those with benign pancreatic neoplasms [6].
Further, Ozkan et al., observed significantly elevated expression of
MIC-1 in PC cases in comparison to other pancreatobilary
diseases and healthy controls. It was found to have similar
sensitivity as that to CA19.9 (81%) in differentiating PC from other
benign diseases [7]. Serum MIC-1 was found to outperform
CA19-9 in CA19-9, in differentiating patients with resectable
pancreatic cancer from controls [8,9].
In the present study, we sought to extend the findings from our
pilot study to investigate the diagnostic utility of plasma NGAL in
PC [3]. Given the participation of both MIC-1 and NGAL in
inflammation and the close relationship between inflammation,
chiefly of the chronic nature, and PC [3], we added MIC-1 to the
panel of potential biomarkers. Plasma CA19-9 was used as
a reference to compare the diagnostic performance of both NGAL
and MIC-1. Our results suggest that plasma levels of both NGAL
and MIC-1 were significantly elevated in patients with PC. In the
present study, MIC-1 was found to be highly specific in
distinguishing patients with surgically resectable PC (i.e. early
stage 1/2) from CP cases. Improved diagnostic efficacy of CA19-9
was observed in differentiating stage 1/2 PC patients from HCs at
an optimal cut-off .54.1 U/ml (74% sensitive and 92% specific)
in comparison to its clinical cut-off (37.1 U/ml) (71% sensitive and
67% specific). Finally, multivariate analysis revealed that a com-
bination of plasma MIC-1 and CA19-9 is significantly superior to
CA19-9 alone in differentiating resectable PC from CP
(AUC = 0.85 vs. 0.74, p = 0.029).
Materials and Methods
Study Design
This retrospective dual center study for plasma markers in PC
was approved by the Institutional Review Boards (IRB) of the
University of Nebraska Medical Center (UNMC) (IRB number
209-00) and the University of Pittsburgh Medical Center (IRB
number PRO07030072). Written informed consent was obtained
from all patients and controls before enrollment into the study.
Inclusion criteria was any adult patient (age $18 years) with
histologically proven PC that that was admitted to the University
of Pittsburgh during the period from 2002 to 2009. Chronic
pancreatitis (CP) was defined based on CT scan findings of
calcifications, abnormal pancreatogram or secretin stimulation
test. For this study, 91 PC, 23 CP patients and 24 healthy controls
were enrolled. Baseline demographic information for all groups is
detailed in Table 1.
For PC patients, a sample was classified as ‘‘treatment naive’’ if
the sample was drawn prior to any cancer-directed surgical or
chemotherapeutic intervention. For diagnostic analyses, only
treatment naı¨ve samples were used. PC staging was based on
one of four criteria: 1) pathological staging post-surgery 2) MRI/
CT/ultrasound staging if this was the only staging available, 3)
endoscopic staging if the patient never underwent surgery or 4)
biopsy of metastatic disease if no previous staging was available.
PC grade, location of the tumor, stage, smoking status, history of
type 2 diabetes and family history of PC were based upon review
of hospital records.
Determination of Plasma NGAL and MIC-1 by Sandwich
ELISA
NGAL and MIC-1 levels in plasma were measured quantita-
tively by sandwich ELISA according to the manufacturer’s
instructions using the DuoSet ELISA kit (R&D Systems) for
human NGAL and MIC-1 respectively. The plasma samples were
stored at 270uC immediately following receipt and aliquoted to
avoid repeated freeze thaw cycles. Standard curves were produced
Table 1. Demographics and clinicopathologic characteristics
of patients included in the study.
Variable HC PC CP p-value
N (%) 24 (17.4%) 91 (66%) 23 (16.6%)
Mean (SD) age 56 (6.7) 65.5 (10.6) 62.6 (11) 0.0005
Males (%) 4 (18%) 55 (60%) 14 (61%) 0.0013
Race
(i) White 20 (91%) 55 (92%) 21 (91%) 0.39
(ii) Black 0 (0%) 4 (7%) 1 (4%)
(iii) Asian 2 (9%) 1 (2%) 1 (4%)
(iv) Missing 2 31 -
Smoker
(i) Ever 2 (25%) 56 (62%) - 0.063
(ii) Never 6 (75%) 35 (38%) -
(iii) Missing 16
BMI 25.6 (5.5)
Stage
1B 5 (6%)
2A 6 (7%)
2B 31 (38%)
3 2 (2%)
4 38 (46%)
Missing 9
Location of tumor
(i) Head 64 (71%)
(ii) Body 16 (17%)
(iii)Tail 8 (9%)
(iv) Uncinate process 2 (2%)
(v) Missing 1
Grade of tumor
(i) Well differentiated 7 (11%)
(ii) Moderately differentiated 30 (45%)
(iii) Poorly differentiated 29 (44%)
(iv) Missing 25
Family History of PC
Present 8 (10%)
Missing 8
History of DM-II 25 (27%)
BMI; Body Mass Index; DM-II: Diabetes Mellitus type II; SD: Standard
Deviation.HC: Healthy Controls; PC: Pancreatic Cancer; CP: Chronic Pancreatitis.
doi:10.1371/journal.pone.0055171.t001
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from NGAL and MIC-1 standards provided with the kit and
serially (log2) diluted from 4 ng/ml to 15.6 pg/ml. All measure-
ments were done in triplicates and samples with readings greater
than that of the highest standard were diluted appropriately and
the assay was repeated. ELISA plates were read at 450 nm with an
absorbance correction at 540 nm. Data collected was analyzed
using the SOFTMAX PRO software (Molecular Devices Corp.,
Sunnyvale, CA).
CA19-9 Radioimmunoassay Assay
CA 19-9 antigen concentration was determined by a solid phase
radioimmunoassay (Centocor, Malvern, PA, USA), using the
manufacturers recommendation. All samples were analyzed in
duplicate and the quantities of CA 19-9 were expressed in
arbitrary units (U/ml) where one unit activity corresponds to
approximately 0.8 ng of purified antigenic protein for CA 19-9 in
a solid phase radioimmunoassay [10].
Statistical Analysis
Data was analyzed using SAS statistical software version 9.2
(SAS Institute Inc, Cary, NC). Age, body mass index (BMI),
plasma levels of CA19-9, NGAL and MIC-1 were analyzed as
continuous variables, while gender, race, tumor grade, cancer
stage, and surgical status were considered to be categorical. Patient
characteristics were compared between PC, CP and control
patients using ANOVA model for continuous variables and chi-
square tests or Fisher’s exact test wherever applicable. Biomarkers
were analyzed on the natural log scale due to the skewed nature of
the data. Biomarkers were compared between groups using t-tests
and ANOVA models. If significant differences were found in the
overall p-values from the ANOVA models then pairwise
comparisons were made adjusting for multiple comparisons with
Tukey’s method.
Logistic regression was used to create ROC (receiver operating
characteristic) curves, which are used to describe the performance
of biomarkers as diagnostic tests that are measured on a continuous
scale. ROC curves are presented using the biomarkers to predict
the diagnosis of pre-treated (i.e. no surgery or chemotherapy) PC
from controls. The area under the curve (AUC) was used to
evaluate the usefulness of a biomarker as a diagnostic test. Odds
ratio (OR) were calculated as a measure of the strength of
association between a biomarker and the disease condition under
Table 2. Comparison of biomarker levels between patient groups.
Healthy Control (n= 24) Pancreatic Cancer# (n = 91) Chronic pancreatitis (n =23)
Mean SD Mean SD Mean SD p-value
CA19-9 (U/mL) 31.5 1.48 219.2 7.77 31.8 2.80 ,0.0001
NGAL (ng/mL) 67.4 1.52 111.1 2.23 111.1 2.14 0.013
MIC-1 (ng/mL) 1.5 4.85 4.5 4.10 1.6 1.80 ,0.0001
SD: Standard deviation. #PC patient samples were limited to treatment naı¨ve samples only for this analysis.
doi:10.1371/journal.pone.0055171.t002
Figure 1. Reciever Operating Chacteristic curves comparing CA19-9 at its clinical cut-off of 37 U/ml and optimal cut-off of 55.1 U/
ml in treatment naı¨ve group. ROC curve analyses for assessing the ability of CA19-9 to differentiate PC form HC (panel A) and PC from CP (panel
B) at its clinical cut off (37 U/ml) (red line), and optimal cut-off (55.1 U/ml) (blue line). At a cutoff of 37 U/mL, CA19-9 differentiated treatment naı¨ve PC
patients from healthy controls with sensitivity, specificity of 83% and 67%, while sensitivity and specificity of 79% and 92% was observed at 55.1 U/
ml. In case of PC vs CP patients, sensitivity and specificity of 61% and 83% were observed at clinical cut-off while at optimal cut-off 62.2 U/ml
sensitivity increased to 79% with specificity of 78%.
doi:10.1371/journal.pone.0055171.g001
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study. For all univariate analyses, PC was considered the disease
state, with CP or healthy controls considered the control group.
Multiple logistic regression was used to evaluate the performance
of the biomarkers in combination as a predictors of pre-treated PC
compared to controls. P-values #0.05 were considered statistically
significant.
Results
Elevated Levels of NGAL, MIC-1, and CA19-9 in Pancreatic
Cancer Patients
Plasma samples from a total of 138 subjects were analyzed
comprised of 91 PC (66%), 23 CP (17%) and 24 healthy control
(HC, 17%) subjects. PC and CP patients were significantly older
than HCs (p = 0.0005) and had a higher percentage of males (60%
and 61% vs. 18%, p = 0.001). A majority of study subjects were
Caucasians (92%, 91% and 91% of PC, CP and HC respectively).
Sixty-two percent of PC and 25% of HC patients were ever
smokers. Nearly half of PC patients had resectable tumors (51%).
A majority of the tumors (71%) were located in the pancreatic
head and were moderate to poorly differentiated (89%). Ten
percent of PC patients had a family history of PC while 27% had
a history of type 2 diabetes (Table 1). Assessment of the
correlation of serum bilirubin with CA19.9 level in both CP and
PC cases revealed no correlation between CA19.9 and bilirubin
levels for PC (r = 0.179 p = 0.080) and CP cases (r = 0.459
p = 0.042). For the present study, due to the skewed distribution
of biomarker levels, each biomarker measurement was log
transformed (into its natural logarithm, to the base e= 2.7183)
prior to comparison of mean levels between the three groups of
patients. For the purposes of presentation, data has been reverse-
log transformed to allow the inclusion of units. The intra and inter-
assay percent coefficient of variation (% CV) for NGAL and MIC-
1 were 4.1%, 14.3%, 5.9% and 16.1% respectively. Due to the
presence of high and low standards built into the commercial kit,
these coefficients were not determined for CA19-9.
The mean plasma concentration (after log transformation) of
NGAL, MIC-1 and CA19-9 were all significantly higher in PC
patients (111.1 ng/mL, 4.5 ng/mL, and 219.2 U/mL) than in the
healthy controls (67.4 ng/mL (p = 0.01), 1.5 ng/mL (p = 0.003),
and 31.5 U/mL (p = 0.001)). Additionally, serum concentration of
MIC-1 and CA19-9, but not NGAL, were found to be higher in
the PC patient group than in CP patients (1.6 ng/mL (p = 0.003),
31.8 U/mL (p,0.001), and 111.1 ng/mL (P.0.05) respectively)
(Table 2).
NGAL levels were significantly higher in patients aged 60 years
or more (p = 0.045). MIC-1 levels were significantly lower in ever
smokers compared to never smokers (p = 0.021). CA19-9 levels on
the other hand were significantly elevated in female PC patients
and in those with unresectable disease (Stage 3/4, p = 0.045 and
0.0047 respectively) (data not shown).
Diagnostic Accuracy of NGAL, CA19-9 and MIC-1
We next sought to investigate the sensitivity and specificity of
the three biomarkers for diagnosing PC. PC patients were divided
either based on disease stage or treatment status. As post-treatment
samples are not diagnostically relevant, only treatment naı¨ve
samples were included in these analyses. In order to check
diagnostic efficacy of CA19-9, MIC-1 and NGAL, these markers
were evaluated at predefined cut-off of $37 U/ml, $1.07 ng/ml,
$106 ng/ml as observed in earlier studies [3,6]. During this
validation, NGAL was found to be 92% sensitive while MIC-1 was
most specific (94%) in distinguishing early stage 1/2 patients from
healthy controls (Table 3). However, overall performance of all
the markers was quite poor. Further, we evaluated their diagnostic
efficacy at optimal cut-off. For CA19-9, apart from the commonly
employed cut-off value of $37 U/ml, we also used optimal cut-off
(55.1 U/ml) as determined by ROC curve analysis. In comparison
of both PC to HC and PC to CP patients, use of an higher cut-off
of CA19-9 resulted in higher specificity with similar sensitivity in
distinguishing PC from either CP or HCs (Figure 1) (Table 4).
For all the further analysis, we used CA19-9 at its optimal cut-off
55.1 U/ml. Notably, CA19-9 at its optimal cut-off was 79%
sensitive and 92% specific in distinguishing treatment naive PC
patients from HCs. MIC-1 was the most sensitive (81%) and
CA19-9 the most specific marker (92%) distinguishing resectable
PC patients (stage 1/2) from HCs. For distinguishing resectable
PC patients from CP patients, MIC-1 was the most specific (78%)
marker and NGAL was the most specific marker (100%) in
distinguishing the stage 3 and 4 PC group from CP cases.
Diagnostic Accuracy of a Combination of Two or Three
Markers for PC Compared to CA19-9 Alone
CA19-9 is currently the only FDA approved biomarker that is
used to aid in the diagnosis and to follow the progress of PC
patients. Having examined the diagnostic performance of in-
dividual markers, we next sought to investigate whether adding
either NGAL or MIC-1 to CA19-9 (the gold standard) improved
the ability to distinguish PC cases (resectable or unresectable) from
Table 3. Diagnostic potential? of NGAL, MIC-1 and CA19-9 at
pre-defined cut-off.
Groups
Pre-defined
cut-off Sensitivity Specificity
PC vs. HC
CA19-9 $37 U/ml 83% 67%
MIC-1 $1.07 ng/ml 90% 46%
NGAL $106 ng/ml 42% 92%
PC vs. CP
CA19-9 $37 U/ml 83% 61%
MIC-1 $1.07 ng/ml 90% 30%
NGAL $106 ng/ml 42% 52%
Stage 1/2 PC vs. HC
CA19-9 $37 U/ml 71% 67%
MIC-1 $1.07 ng/ml 94% 46%
NGAL $106 ng/ml 46% 92%
Stage 3/4 PC vs. HC
CA19-9 $37 U/ml 88% 67%
MIC-1 $1.07 ng/ml 90% 46%
NGAL $106 ng/ml 44% 92%
Stage 1/2 PC vs. CP
CA19-9 $37 U/ml 71% 61%
MIC-1 $1.07 ng/ml 94% 30%
NGAL $106 ng/ml 46% 52%
Stage 3/4 PC vs. CP
CA19-9 $37 U/ml 88% 61%
MIC-1 $1.07 ng/ml 90% 30%
NGAL $106 ng/ml 44% 52%
?PC patient samples were limited to treatment naı¨ve samples only for this
analysis.
doi:10.1371/journal.pone.0055171.t003
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CP or HCs. The combination tests were determined via
multivariate analyses of individual markers, and those showing
statistically significant differences between respective patient
groups being used further for analysis. Addition of NGAL and
MIC-1 improved the area under the curve (AUC6SE) from 0.8
(0.06) to 0.85 (0.05) in distinguishing stage1/2 PC from HCs
(Table 5). The addition of NGAL (with or without MIC-1) had
significant impact on the ability of CA19-9 to distinguish PC
(either resectable or unresectable) from HCs. Notably, the addition
of MIC-1 to CA19-9 significantly improved the ability to
distinguish resectable PC cases from CP (AUC 0.74 with CA19-
9 alone and 0.85 with the combination (C.I. 0.76–0.94) (Figure 2)
(Table 5). Further, addition of NGAL improved the AUC from
0.89 (0.05) to 0.94 (0.03) in distinguishing stage 3/4 PC from HCs.
Discussion and Conclusions
The management of PC would greatly benefit from an early
diagnostic biomarker. Various potential candidates have been
tested but none have been consistently found superior to CA19-9.
Recently, our group observed de novo expression of NGAL
(acronym for neutrophil gelatinase associated lipocalin), a 25 kDa
secreted glycoprotein, in PanIN-1s, the earliest premalignant
lesions preceding PC. Further, we noted in a limited set of patient
samples that serum NGAL levels were significantly elevated in the
plasma of patients with CP and PC compared to healthy
individuals (p = 0.035 and 0.004 respectively) [3]. Koopman et al,
had reported in an earlier study that another small cytokine MIC-
1 (macrophage inhibitory cytokine 1) could distinguish PC patients
from HCs with a sensitivity and specificity of 94% and 90%
respectively [6]. As both MIC-1 and NGAL are small, secreted
glycoproteins, we hypothesized that a combination of these two
markers could discriminate PC patients from HCs and CP
patients. To investigate this hypothesis, we compared their
diagnostic accuracy with that of CA19-9, the current gold
standard marker for PC. The results of our study suggest that
NGAL and MIC-1 may be at least comparable to CA19-9 in their
Table 4. Determining optimum cut-off of CA19-9, NGAL and MIC-1 for diagnosis of pancreatic cancer?.
Groups Optimum cut-off Sensitivity Specificity
OR from cut-
point 95% CI p-value
PC vs. HC
CA19-9 $37 U/ml 83% 67% 8.4 2.8–25.8 0.0002
ln (CA19-9) .55 U/ml 79% 92% 40.7 8.2–203 ,0.0001
ln (MIC-1) .2.3 ng/ml 62% 63% 2.7 0.97–7.4 0.056
ln (NGAL) .83 ng/ml 67% 57% 2.7 0.97–7.5 0.058
PC vs. CP
CA19-9 $37 U/ml 83% 61% 6.6 2.2–19.9 0.0009
ln (CA19-9) .62.2 U/ml 79% 78% 13.3 4.0–44.8 ,0.0001
ln (MIC-1) .2.3 ng/ml 62% 78% 5.8 1.8–18.4 0.0028
ln (NGAL) .157.6 ng/ml 34% 65% 0.97 0.3–2.8 0.95
Stage 1/2 PC vs. HC
CA19-9 $37 U/ml 71% 67% 7.3 2.4–22.6 0.0005
ln (CA19-9) .54.1 U/ml 74% 92% 31 6.2–153.9 ,0.0001
ln (MIC-1) .2.2 ng/ml 81% 64% 6 1.9–18.2 0.0018
ln (NGAL) .91.8 ng/ml 64% 88% 12.6 3.2–49.3 0.0003
Stage 3/4 PC vs. HC
CA19-9 $37 U/ml 88% 67% 18 4.7–68.5 ,0.0001
ln (CA19-9) .54.1 U/ml 83% 92% 51.9 9.8–273 ,0.0001
ln (MIC-1) .1.6 ng/ml 78% 58% 4.8 1.6–14.5 0.005
ln (NGAL) .86.5 ng/ml 58% 79% 5.1 1.6–16.5 0.006
Stage 1/2 PC vs. CP
CA19-9 $37 U/ml 71% 61% 5.7 1.9–17.4 0.0022
ln (CA19-9) .49.4 U/ml 76% 74% 9.1 2.8–29.2 0.0002
ln (MIC-1) .2.3 ng/ml 76% 78% 11.5 3.4–39 ,0.0001
ln (NGAL) .70.8 ng/ml 76% 30% 1.4 0.4–4.36 0.56
Stage 3/4 PC vs. CP
CA19-9 $37 U/ml 88% 61% 14 3.7–52.9 0.0001
ln (CA19-9) .186 U/ml 70% 96% 51.3 6.2–425 0.0003
ln (MIC-1) .3.5 ng/ml 55% 91% 12.8 2.6–62.2 0.0015
ln (NGAL) .-28.5 ng/ml 5% 100% ND ND ND
HC: Healthy Controls; CP: Chronic Pancreatitis; PC: Pancreatic Cancer; ln: natural log; ND: Not Determined.?PC patient samples were limited to treatment naı¨ve samples
only for this analysis.
doi:10.1371/journal.pone.0055171.t004
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diagnostic accuracy in specific situations. Specifically, MIC-1 has
sensitivity and specificity similar to CA19-9 (at its optimal cut-off)
in distinguishing treatment naı¨ve PC patients from CP patients
(Table 4). Further, the addition of MIC-1 (with or without
NGAL) improved the ability to distinguish both resectable (stage 1
or 2, p = 0.029) and unresectable (stage 3 or 4, p = 0.079) PC from
CP patients (Table 5).
NGAL and its murine homologue Ngal have been proposed as
components of the innate immune system [11–13]. In our earlier
studies, we observed that overexpression of NGAL in PC cells
inhibit invasion and metastasis and prevents angiogenesis [14].
The observation that NGAL levels are similar in CP and PC
patients (Table 2) suggests that NGAL may be released as a part
of the chronic inflammatory response that accompanies both
diseases.
Figure 2. Reciever Operating Chacteristic curves comparing NGAL, MIC-1, CA19-9 for differentiating PC from HC (panel A) and CP
(panel B) and combination of CA19-9 and MIC-1 in differentiating treatment naı¨ve resectable PC from CP. The combined use of MIC-1
with CA 19-9 significantly improved the sensitivity and accuracy in differentiating resectable PC from CP (AUC = 0.85 Vs 0.74, p = 0.029, C.I. 0.76–0.94)
in comparison to CA19-9 alone.
doi:10.1371/journal.pone.0055171.g002
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MIC-1 (also called as GDF-15 or NAG-1) is a member of the
TGF-b family that was first identified as a protein secreted from
macrophages in response to immune activation [15]. MIC-1 is also
aberrantly expressed by several malignancies (including PC) and
has emerged as target of p53 mediated transcription (role of MIC-
1 in cancer reviewed in [15]). Differential expression of MIC-1 was
observed in SAGE (serial analysis of gene expression) libraries
from six pancreatic cancer cell lines in comparison to non-
neoplastic tissues [16]. Koopman and colleagues had reported
earlier that MIC-1 was significantly better than CA19-9 in
discriminating PC from HCs (AUC being 0.99 and 0.78,
p = 0.003) but not from CP (AUC being 0.81 and 0.74
respectively, p = 0.63) [6]. They observed that the mean MIC-1
level in healthy controls, CP and PC was 0.76 ng/ml, 2.36 ng/ml
and 5.4 ng/ml respectively. Further studies emphasized the
diagnostic efficacy of MIC-1 equivalent to CA19-9 [6,7]. In our
study, the mean plasma MIC-1 levels in these patient groups were
1.5 ng/ml, 1.6 ng/ml and 4.5 ng/ml (Table 2). In our sample
set, at an optimal cut-off of .2.3 ng/ml, plasma MIC-1 was 62%
sensitive and 63% specific in discriminating PC from HCs. At this
cut-off, MIC-1 was 78% specific and 62% sensitive in differen-
tiating PC from CP patients. Interestingly, the combined use of
MIC-1 with CA 19-9 significantly improved the sensitivity and
accuracy in differentiating resectable PC (Stage 1/2) patients from
CP patients (AUC of 0.85, p = 0.029) in comparison to CA19-9
alone (AUC of 0.74), providing a promising approach for PC
diagnosis at an early stage. The significance of MIC-1 as
a biomarker for PC will need to be investigated in larger patient
cohorts.
CA19-9 is a well-known molecular marker in PC. Biochemi-
cally, it is the sialylated Lewis antigen present on several
glycoproteins. Overall, it has a reported sensitivity and specificity
of between 70%–80% and 70%–90% respectively [17,18].
However, its major drawback is that it can also be positive in
several benign conditions [1,19]. In our study, we observed that
CA19-9 at the commonly employed cut-off of .37 U/ml was
83% sensitive and 67% specific in distinguishing PC patients from
HCs and 83% sensitive with 61% specificity in differentiating PC
patients from CP. Interestingly, the optimal cut-offs for CA19-9 as
a diagnostic marker (55 U/ml, 79% sensitive and 92% specific in
distinguishing PC patients from HCs and 62.2 U/mL, 79%
sensitive and 78% specific in differentiating PC patients from CP)
were higher than the common clinically employed cut-off of
37 U/ml. These higher cut-offs, though yielding similar sensitiv-
ities, increased the specificity of CA19-9 (Table 4). This
observation suggests that no one single cut-off for CA19-9 (or
for that matter any other biomarker) is applicable to all situations.
Additionally Morris-stiff et al., observed that elevated levels of
CA19-9 correlated directly with the degree of biliary obstruction
(r= 0.911, P,0.001) but for malignant diseases CA19-9 levels were
elevated independent of bilirubin (r= 0.117288, P= 0.603) [20].
Similarly, we assessed the correlation of serum bilirubin with
CA19.9 level in both CP and PC cases. However, no correlation
was observed between CA19.9 and bilirubin levels for PC
(r = 0.179 p = 0.080) and CP cases (r = 0.459 p = 0.042). Larger
studies in the future will aim to assess the impact of each of these
cut-offs in distinguishing specific groups.
A limitation of the present study is the lack of information on
the prognostic significance of NGAL and MIC-1 in PC. Elevated
NGAL levels have been reported in earlier studies to correlate with
reduced survival in ovarian [21] breast [22] and gastric cancer
[23] patients while MIC-1 levels did not show any correlation with
survival in oesophageal cancer [24] but, when elevated in the
cerebrospinal fluid, was associated with a shorter survival in
patients with glioblastomas [25]. Additionally, the study involved
51% of the PC patients with resectable (Stage 1/2) tumor (early
stage tumor), a scenario quite different from clinics. Thus
diagnostic efficacy of these markers might vary according to the
population set. Future studies will seek to answer this question to
better delineate the clinical applicability of these biomarkers in the
management of PC.
The strength of our study is the rigorous design and techniques
used. Specifically, Koopman and colleagues had employed ELISA
to measure both CA19-9 and MIC-1. However, clinically, CA19-9
levels are commonly measured by radioimmunoassay (RIA).
Initially, we tried employing ELISA to measure CA19-9 to try
and keep our methodology as similar to the earlier study as
possible. However, we noted that the measurements using ELISA
lacked reproducibility (data not shown). Hence, we then re-
analyzed all samples for CA19-9 levels by RIA. Thus, the study
was not only an investigational study but also served to validate
previous studies. Based on our observations, we agree with
employing the RIA technique for reproducible measurement of
CA19-9.
In summary, we have investigated whether quantitative
measurement of NGAL, MIC-1 and CA19-9 could be useful in
the diagnosis of PC. We observed that while the level of all three
biomarkers was significantly elevated in PC in comparison to HCs,
only CA19-9 and MIC-1 were significantly elevated in CP patients
compared to HCs. Log transformed value of NGAL was more
specific than CA19-9 in distinguishing stage 3/4 PC patients from
CP cases while that of MIC-1 was more sensitive (stage 1/2 PC
from HCs) or specific (stage 1/2 vs CP) than CA19-9 in a sub-
group specific manner. CA19-9 performed better in distinguishing
PC form CP patients or HCs at a higher cut-off value than the
commonly employed cut-off of 37 U/ml. A combination of MIC-1
and CA19-9 was better than the latter alone in distinguishing
Table 5. Comparison of Area under the ROC curve for NGAL,
MIC-1 and CA19-9 in the diagnosis of pancreatic cancer?.
Groups AUC (SE) 95% CI p-valuea
Stage 1/2 PC vs. HC
ln CA19-9 0.8 (0.06) 0.69–0.91
ln NGAL+ln CA19-9 0.82 (0.05) 0.72–0.93 0.4
ln NGAL+ln CA19-9+ ln MIC1 0.85 (0.05) 0.75–0.94 0.22
Stage 3/4 PC vs. HC
ln CA19-9 0.89 (0.05) 0.80–0.98
ln NGAL+ln CA19-9 0.94 (0.03) 0.87–1.00 0.11
ln NGAL+ln CA19-9+ ln MIC1 0.94 (0.03) 0.89–1.00 0.13
Stage 1/2 PC vs. CP
ln CA19-9 0.74 (0.06) 0.62–0.87
ln MIC-1+ ln CA19-9* 0.85 (0.05) 0.76–0.94 0.029
ln NGAL+ln CA19-9+ ln MIC1 0.86 (0.04) 0.77–0.95 0.027
Stage 3/4 PC vs. CP
ln CA19-9 0.87 (0.04) 0.79–0.96
ln MIC-1+ ln CA19-9* 0.93 (0.03) 0.87–0.99 0.079
ln NGAL+ln CA19-9+ ln MIC1 0.92 (0.03) 0.86–0.99 0.12
PC (pancreatic cancer), CP (chronic pancreatitis), AUC (area under the curve), SE
(standard error). aP-value against CA19-9 alone.*Marker inclusion in
combination tests was based on statistical significance of differentiation of
individual biomarkers levels by multivariate analysis). ?PC patient samples were
limited to treatment naı¨ve samples only for this analysis.
doi:10.1371/journal.pone.0055171.t005
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resectable PC from CP patients while addition of NGAL improved
the ability of CA19-9 to distinguish stage 3/4 PC cases from HCs.
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